75 Olaparib in patients with biallelic BRCA1/2 inactivation Supplementary Table 1. For each patient, an overview of clinical characteristics (tumor type, response to therapy, previous treatments) and molecular characteristics (pre-enrollment and at baseline) is presented. $ = For details regarding the functional tests, please refer to the results section in the main text Patient had clinical benefit Patient had no clinical benefit * Patient was not evaluable for primary end point and was not included in the efficacy analysis (Table starts on next page) 3
RkJQdWJsaXNoZXIy MTk4NDMw